Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 11
Submit an article Journal homepage
357
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

James A. Davisa Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7978-1652
ORCID Icon,
David A. Rizzierib Duke Cancer Institute, Durham, NC, USA
,
Andrew A. Lanec Medical Oncology, Dana Farber – Harvard Institute, Boston, MA, USA
,
Justin Taylord University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA
,
Muhammad Salman Faisale Division of Hematology, The Ohio State University, Columbus, OH, USA
,
Sumithira Vasue Division of Hematology, The Ohio State University, Columbus, OH, USA
,
Deborah Soongd University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA
,
Hong Lia Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
,
Amanda Herbsta Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
&
I. Brian Greenwella Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
 show all
Pages 2757-2759 | Received 11 Mar 2022, Accepted 07 Jun 2022, Published online: 21 Jun 2022

References

  • Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239–246.
  • Bueno C, Almeida J, Lucio P, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1):58–69.
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
  • Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628–1637.
  • Pemmaraju N, Wilson NR, Khoury JD, et al. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021;138(15):1373–1377.
  • Martín-Martín L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult Central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7(9):10174–10181.
  • Laribi K, Baugier de Materre A, Sobh M, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv. 2020;4(19):4838–4848.
  • Valentini CG, Piciocchi A, Facchetti F, et al. Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey. Blood Adv. 2021;5(24):5608–5611.
  • Taylor J, Haddadin M, Upadhyay VA, et al. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019;134(8):678–687.
  • FDA. Hematology/Oncology (cancer) approvals & safety notifications; [cited 2021 Oct 11]. Available from:www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications.
  • Salem A. Venetoclax crosses the blood brain barrier: a pharmacokinetic analysis of the cerebrospinal fluid in pediatric leukemia patients. In ASH; 2020; [cited 2022 Mar 10]. Available from: https://ash.confex.com/ash/2020/webprogram/Paper137197.html.
  • de Vos S, Swinnen LJ, Wang D, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1932–1938.
  • Reda G, Cassin R, Dovrtelova G, et al. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with Central nervous system involvement. Haematologica. 2019;104(5):e222–3–e223.
  • Chabot GG, Rivard GE, Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2’-deoxycytidine in rabbits and dogs. Cancer Res. 1983;43(2):592–597.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.